SOHO State of the Art and Next Questions: Management of Myelodysplastic Syndromes with Deletion 5q

Publication date: Available online 30 July 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Chetasi Talati, David Sallman, Alan F. ListAbstractMyelodysplastic syndrome (MDS) with deletion 5q (del(5q)) is a distinct clinical and pathological disease subset that is exquisitely sensitive to lenalidomide for the treatment of red blood cell transfusion-dependent anemia. Lenalidomide resistance, including primary resistance occurs via clonal evolution which is frequently attributable to the presence of somatic mutations in in the DNA-binding domain of the TP53 gene. Treatment options after development of resistance to lenalidomide are limited and comprise of hypomethylating agents, clinical trials and allogeneic hematopoietic stem cell transplant. We discuss evidence-based strategies devising a treatment algorithm for patients with MDS with del(5q).
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research